La terapia del diabete nel paziente nefropatico

La terapia del diabete nel paziente nefropatico

Abstract non disponibile

Bibliographic Details
Main Authors:	Edoardo Mannucci, Ilaria Dicembrini
Format:	Article
Language:	Italian
Published:	AboutScience Srl 2015-06-01
Series:	Giornale di Clinica Nefrologia e Dialisi
Subjects:	GLP-1 receptor agonists SGLT-2 inhibitors Renal impairment
Online Access:	https://journals.aboutscience.eu/index.php/gcnd/article/view/801

Similar Items

Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
by: Takayuki Yamada, et al.
Published: (2021-01-01)

Benzodiazepine: indicazioni terapeutiche e utilizzo nel paziente nefropatico
by: Maria Josè Sequenza, et al.
Published: (2013-12-01)

The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies
by: Devinder S. Dhindsa, et al.
Published: (2018-11-01)

Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
by: Heeyoung Lee, et al.
Published: (2021-09-01)

Combination therapy with SGLT2 inhibitors for diabetic kidney disease
by: Yuwen Cai, et al.
Published: (2020-07-01)

Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis
by: Maria Mirabelli, et al.
Published: (2020-05-01)

SAVOR-TIMI to DECLARE-TIMI: A review on cardiovascular outcome trials of incretin-modulators and gliflozins
by: Awadhesh K Singh, et al.
Published: (2019-01-01)

Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes
by: Vjera Ninčević, et al.
Published: (2019-11-01)

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
by: Honghong Zou, et al.
Published: (2017-05-01)

NEW APPROACHES IN THE TREATMENT OF TYPE 2 DIABETES - TRANSITION FROM GLUCOSE-CENTRED TO PATIENT-CENTRED MODEL
by: Antoaneta Tsvetkova, et al.
Published: (2021-08-01)

Association of Antihyperglycemic Therapy with Risk of Atrial Fibrillation and Stroke in Diabetic Patients
by: Cristina-Mihaela Lăcătușu, et al.
Published: (2019-09-01)

Current Data Regarding the Relationship between Type 2 Diabetes Mellitus and Cardiovascular Risk Factors
by: Cosmin Mihai Vesa, et al.
Published: (2020-05-01)

Cardiovascular outcomes of antidiabetic drugs
by: Ranjit Kumar Nath, et al.
Published: (2021-03-01)

Anti-diabetic Agents and the Potentials for Reducing Cardiovascular Risks in Type-2 Diabetes Mellitus
by: Ezeani IU, et al.
Published: (2021-09-01)

Role of metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) receptor agonists, and orlistat based multidrug therapy in glycemic control, weight loss, and euglycemia in diabesity: A real-world experience
by: Deep Dutta, et al.
Published: (2019-01-01)

Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
by: Andrea Natali, et al.
Published: (2021-09-01)

The latest recommendations of the Polish Diabetes Association and the American Diabetes Association in the treatment of diabetes with modern drugs
by: Szymon Marosz, et al.
Published: (2020-09-01)

Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
by: Da-Peng Zhang, et al.
Published: (2020-01-01)

The treatment of diabetes with new generation drugs
by: Szymon Jan Marosz, et al.
Published: (2020-09-01)

Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis
by: Yoon Ji Kim, et al.
Published: (2020-08-01)

Heart failure in diabetes: From an increased risk to a treatment target
by: Eberhard Standl
Published: (2018-12-01)

Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
by: Schernthaner G, et al.
Published: (2017-12-01)

Repurposing Antidiabetic Drugs for Cardiovascular Disease
by: Mario Schubert, et al.
Published: (2020-09-01)

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial
by: IJzerman, R.G, et al.
Published: (2022)

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
by: Lindsay E. Clegg, et al.
Published: (2019-10-01)

Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials
by: Lisa Ludwig, et al.
Published: (2020-05-01)

Management and prevention of cardiovascular disease for type 2 diabetes: Integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC
by: Zachary Bloomgarden, et al.
Published: (2020-03-01)

Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes
by: Chan Uk Heo, et al.
Published: (2019-03-01)

Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH
by: Katharina Luise Hupa-Breier, et al.
Published: (2021-03-01)

The role of novel antihyperglycaemic agents in the treatment of Type 2 diabetes: From glycaemic control to cardiovascular protection
by: Žunić Tatjana, et al.
Published: (2020-01-01)

Nephroprotective properties of glucose-lowering drugs
by: Elena V. Pokrovskaya, et al.
Published: (2019-04-01)

Activation of the renal GLP‐1R leads to expression of Ren1 in the renal vascular tree
by: Katrine Dahl Bjørnholm, et al.
Published: (2021-07-01)

Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
by: Mariusz Dąbrowski
Published: (2021-02-01)

Evaluating the Diabetes–Cardiology interface: a glimpse into the diabetes management of cardiology inpatients in western Sydney’s ‘diabetes hotspot’ and the establishment of a novel model of care
by: Ramy H. Bishay, et al.
Published: (2018-12-01)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
by: Thompson AM, et al.
Published: (2016-05-01)

GLP-1 Receptor: A New Target for Sepsis
by: Fuxun Yang, et al.
Published: (2021-07-01)

Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption
by: Hideki Kitaura, et al.
Published: (2021-06-01)

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
by: Yushmanova Irina, et al.
Published: (2011-03-01)

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
by: Chun-Ting Yang, et al.
Published: (2020-06-01)

Trapianto Renale Da Donatore Vivente: Il Giovane Nefrologo Lo Consiglia Al Giovane Paziente Nefropatico
by: Chiara Caletti
Published: (2014-02-01)